Designing and development of phthalimides as potent anti-tubulin hybrid molecules against malaria

Eur J Med Chem. 2022 Sep 5:239:114534. doi: 10.1016/j.ejmech.2022.114534. Epub 2022 Jun 15.

Abstract

Constant emergence of drug-resistant Plasmodium falciparum warrants urgent need for effective and inexpensive drugs. Herein, phthalimide (Pht) analogs possessing the bioactive scaffolds, benzimidazole and 1,2,3-triazole, were evaluated for in vitro and in vivo anti-plasmodial activity without any apparent hemolysis, or cytotoxicity. Analogs 4(a-e) inhibited the growth of 3D7 and RKL-9 strains at submicromolar concentrations. Defects were observed during parasite egress from or invasion of the red blood cells. Mitochondrial membrane depolarization was measured as one of the causes of cell death. Phts 4(a-e) in combination with artemisinin exhibited two-to three-fold increased efficacy. Biophysical and biochemical analysis suggest that Pht analogs mediate plasmodial growth inhibition by interacting with tubulin protein of the parasite. Lastly, Phts 4(a-e) significantly decreased parasitemia and extended host survival in murine model Plasmodium berghei ANKA infection. Combined, the data indicate that Pht analogs should be further explored, which could offer novel value to the antimalarial drug development pipeline.

Keywords: Antimalarial; Drug discovery; Drug resistance; Phthalimide analogs; Plasmodium falciparum; Tubulin.

MeSH terms

  • Animals
  • Antimalarials* / chemistry
  • Malaria* / drug therapy
  • Malaria* / parasitology
  • Mice
  • Phthalimides / chemistry
  • Phthalimides / pharmacology
  • Plasmodium berghei
  • Plasmodium falciparum
  • Tubulin

Substances

  • Antimalarials
  • Phthalimides
  • Tubulin